Physician profile
John Bunker
NPI 1295363455
$3,267.97
in general payments reported to CMS, 2019-2025
16 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $139 · 2024: $705 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,484.76 | 2025 | Rapiblyk |
| Pfizer INC. | $276.45 | 2024-2025 | |
| Abbvie INC. | $229.49 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.21 | 2024-2025 | Xifaxan |
| Csl Behring | $187.87 | 2023-2025 | Kcentra |
| Alexion Pharmaceuticals, INC. | $172.09 | 2023-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.11 | 2023-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $140.68 | 2025 | Vowst |
| Ferring Pharmaceuticals INC. | $137.84 | 2023-2025 | Rebyota |
| Janssen Pharmaceuticals, INC | $76.35 | 2024 | Xarelto |
| Vertex Pharmaceuticals Incorporated | $68.18 | 2025 | |
| Shionogi INC | $59.86 | 2023-2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $35.11 | 2024 | Nuzyra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.76 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2025 | Eliquis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $17.01 | 2025 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bunker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.